GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Alpha Tau Medical Ltd.
Alpha Tau Medical has developed an innovative radiation therapy technology for cancer treatment. Its stock price represents a venture capital bet that its method will prove more effective and safer than existing ones. The chart reflects the results of clinical trials and investor expectations.
Share prices of companies in the market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology, Alpha DaRT, for the treatment of solid tumors, which destroys cancer cells with minimal damage to healthy tissue. We have classified it in the "Miscellaneous Oncology" segment. The graph below shows the overall dynamics in the oncology technology sector, where new methods for fighting cancer are constantly being sought.
Broad Market Index - GURU.Markets
Alpha Tau Medical is an Israeli medical company that has developed innovative alpha radiotherapy that destroys solid tumors with minimal damage to healthy tissue. As a component of the GURU.Markets index, it represents the nuclear medicine sector. The chart below represents the entire market. See how Alpha Tau shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
DRTS - Daily change in the company's share price Alpha Tau Medical Ltd.
The daily price change of Alpha Tau, an oncology company, is a measure of its sensitivity to clinical trial results. Change_co reflects the high volatility inherent in the biotech sector. This metric is important for formulas on System.GURU.Projects that analyze companies developing new cancer treatments.
Daily change in the price of a set of shares in a market segment - Miscellaneous oncology
Alpha Tau Medical Ltd. is an oncology company. This chart demonstrates the extreme volatility of the MedTech sector. Comparison with the dynamics of DRTS, with its unique radiation therapy technology, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Alpha Tau is an oncology company that has developed innovative radiation therapy technology. The biotech sector is extremely volatile, and Alpha Tau's story is a prime example. The chart below reflects the average fluctuations in this industry, providing context for evaluating the company's stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd.'s year-over-year performance is a story about the development of an innovative cancer treatment using alpha radiation. Its 12-month market cap depends on the results of clinical trials of its Alpha DaRT technology. Successful data demonstrating efficacy and safety are key to its future valuation.
Annual dynamics of market capitalization of the market segment - Miscellaneous oncology
Alpha Tau Medical Ltd. is developing an innovative radiation therapy technology for cancer treatment. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alpha Tau, with its innovative cancer treatment technology, is a high-risk, high-potential story. Its stock price is entirely dependent on clinical trial results. The chart isn't about economics, but rather whether investors believe its revolutionary approach will become a new standard in oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Alpha Tau Medical Ltd.
Alpha Tau, a healthcare company, is a speculative company. Monthly fluctuations on the chart reflect not revenue, but news about clinical trials of its innovative radiation therapy for cancer, the success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology for solid tumors that delivers alpha radiation directly to cancer cells. The company's success depends on clinical data and acceptance of its method. The oncology sector's growth will reflect overall interest in new treatments, providing a backdrop for assessing Alpha Tau's breakthrough potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alpha Tau Medical is developing innovative radiation therapy for cancer treatment. The company's shares, like many in the biotech sector, have a life of their own. Their price reflects hopes for the success of the new technology. Clinical trial data and regulatory announcements have a much greater impact on the stock than overall market fluctuations.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Alpha Tau Medical Ltd.
Alpha Tau Medical has developed an innovative radiation therapy technology for cancer treatment. Its weekly stock price, like that of many medical startups, is reflecting the publication of clinical data, regulatory approvals, and news of the implementation of its method at leading cancer centers.
Weekly dynamics of market capitalization of the market segment - Miscellaneous oncology
The innovative oncology sector, where Alpha Tau Medical operates, is driven by expectations of breakthrough technologies. The chart below reflects the general sentiment in this niche. It helps understand how unique and promising the market perceives Alpha Tau's technology compared to developments by other cancer companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Alpha Tau Medical has developed innovative radiation therapy for the treatment of solid tumors. This is a breakthrough technology in oncology. The chart will show how its shares follow their own news cycle, responding to clinical data rather than general market fluctuations.
Market capitalization of the company, segment and market as a whole
DRTS - Market capitalization of the company Alpha Tau Medical Ltd.
Alpha Tau Medical's market capitalization chart reflects investors' bets on its innovative cancer treatment technology. Its dynamics reflect the market's faith in Alpha DaRT, which uses alpha radiation to destroy solid tumors. Its price reflects the potential of this new radiotherapy method, currently in clinical trials.
DRTS - Share of the company's market capitalization Alpha Tau Medical Ltd. within the market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology for the treatment of solid tumors. Its market capitalization in the oncology equipment segment reflects the revolutionary potential of its method. Its growth is directly related to successful clinical results and investor confidence that this technology will become a new standard in cancer treatment.
Market capitalization of the market segment - Miscellaneous oncology
This graph shows the total value of the entire oncology sector. For Alpha Tau Medical, with its innovative precision radiation therapy technology, this line demonstrates the scale of the battle against cancer. The rising graph reflects billions of dollars invested in new treatments and demonstrates the enormous market the company's breakthrough technology is targeting.
Market capitalization of all companies included in a broad market index - GURU.Markets
Alpha Tau Medical has developed a new radiation therapy technology for the treatment of solid tumors. Its market cap represents the valuation of this potentially revolutionary method in oncology. Within the overall market, this represents the share investors are willing to allocate to this fundamentally new approach to fighting cancer.
Book value capitalization of the company, segment and market as a whole
DRTS - Book value capitalization of the company Alpha Tau Medical Ltd.
Alpha Tau Medical has developed innovative radiation therapy for cancer treatment. Its book value is its scientific and production capital: patents for the Alpha DaRT technology, R&D centers, and equipment. This is the material basis for this new method of fighting tumors. How has this capital grown? The chart below shows.
DRTS - Share of the company's book capitalization Alpha Tau Medical Ltd. within the market segment - Miscellaneous oncology
Alpha Tau Medical Ltd. has developed an innovative cancer treatment method, and the manufacturing infrastructure behind it is behind it. The company is building factories to produce its "alpha-emitting seeds," its unique product. The graph shows its share of the physical resources needed to create this new type of radiation therapy.
Market segment balance sheet capitalization - Miscellaneous oncology
Alpha Tau Medical is developing a new radiation therapy. Its business is capital-intensive, as it requires the production of radioactive "seeds" and delivery systems. The BCap_Seg chart for the medical equipment sector shows that breakthrough treatments require a significant material and scientific base.
Book value of all companies included in the broad market index - GURU.Markets
Alpha Tau Medical's capital is not in its drugs, but in its unique Alpha DaRT technology for treating solid tumors with alpha radiation. Its assets include patents, research data, and manufacturing equipment. The chart shows the material value of this innovative radiology platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Alpha Tau Medical Ltd.
Alpha Tau's balance sheet is its R&D capital. Its entire market value is a premium on its revolutionary Alpha DaRT cancer treatment technology. Its price is a bet that this new type of radiation therapy will prove a breakthrough in oncology.
Market to book capitalization ratio in a market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative method of radiation therapy for cancer. Its high ranking on this chart reflects its bet that its Alpha DaRT technology will become a new standard in oncology, despite being in the early stages of commercialization and requiring further research.
Market to book capitalization ratio for the market as a whole
Alpha Tau Medical is developing a new form of radiation therapy for cancer treatment. The company's value lies in its unique technology and potential to change the standard of care. Its market valuation is a multiple of its book value, reflecting investor hopes for a medical breakthrough rather than its current tangible assets.
Debts of the company, segment and market as a whole
DRTS - Company debts Alpha Tau Medical Ltd.
Alpha Tau Medical, a company developing innovative radiation therapy for cancer treatment, uses capital to conduct clinical trials and commercialize its technology. This chart shows how the MedTech startup finances its journey from scientific concept to approved medical device, which requires significant and risky investments.
Market segment debts - Miscellaneous oncology
Alpha Tau Medical is developing innovative radiation therapy for the treatment of solid tumors. Like any medical company in the commercialization stage, it has significant expenses for clinical trials and marketing. This chart shows how the company is funding the commercialization of its unique technology and how much it relies on debt capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Alpha Tau Medical Ltd.
Alpha Tau Medical is developing an innovative radiation therapy for cancer treatment. Like many medical startups, its path to market requires significant capital investment. This chart shows the company's use of debt to fund clinical trials and research. It reflects its high level of risk and belief in the breakthrough potential of its technology.
Market segment debt to market segment book capitalization - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology for the treatment of solid tumors. Bringing this new medical approach to market requires significant investment in clinical trials. The chart shows the sector's debt load, providing context for assessing how the company is financing its breakthrough technology.
Debt to book value of all companies in the market
Alpha Tau Medical is developing innovative radiation therapy for cancer treatment. This process requires significant investment in clinical trials and equipment. This chart shows the overall market debt burden. It allows one to assess how the company is financing its path to commercialization and how its debt strategy is typical for the medical technology sector.
P/E of the company, segment and market as a whole
P/E - Alpha Tau Medical Ltd.
Alpha Tau Medical has developed an innovative radiation therapy technology, Alpha DaRT, for the treatment of solid tumors. This chart shows how investors value its revolutionary approach to cancer treatment. The company's valuation depends not on current profits, but on the results of clinical trials and the potential of this technology.
P/E of the market segment - Miscellaneous oncology
Alpha Tau Medical is developing a new radiation therapy technology. This chart shows the average valuation for the medical device sector. It emphasizes that Alpha Tau is valued not by current sales, but by the revolutionary potential of its cancer treatment technology, which the market can value at a significant premium.
P/E of the market as a whole
Alpha Tau Medical Ltd. is developing an innovative radiation therapy technology, Alpha DaRT, for the treatment of solid tumors. This method destroys cancer cells with minimal damage to healthy tissue. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether DRTS's valuation reflects faith in its unique technology or is part of the overall optimism in the sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Alpha Tau Medical Ltd.
Alpha Tau Medical has developed an innovative radiation therapy technology for the treatment of solid tumors. The company's future revenue depends on the clinical success and adoption of this method. This chart reflects market expectations regarding the potential of its technology to become a new standard in localized cancer treatment.
%20P%2FE%20Alpha%20Tau%20Medical%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alpha-Tau-Medical-Ltd.&v=1772618192603 "Chart of the company's future (projected) P/E Alpha Tau Medical Ltd.")
Future (projected) P/E of the market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology, Alpha DaRT, for the treatment of solid tumors, which delivers alpha particles directly to cancer cells. The data presented here reflects the collective betting of analysts on the success of this breakthrough technology, reflecting expectations that it could change the paradigm of cancer treatment.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Miscellaneous-oncology&v=1772618192637 "Future (projected) P/E graph of the market segment - Miscellaneous oncology")
Future (projected) P/E of the market as a whole
Alpha Tau Medical has developed an innovative radiation therapy for treating solid tumors. This potentially revolutionary approach to oncology. This sentiment chart shows how willing investors are to invest in breakthrough medical technologies that could change the standard of cancer treatment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772618192644 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Alpha Tau Medical Ltd.
Alpha Tau Medical has developed an innovative radiation therapy that destroys solid tumors with minimal damage to healthy tissue. This chart shows the financial costs of implementing this new medical technology. It reflects the investment in clinical trials to prove the effectiveness of this breakthrough method.
Profit of companies in the market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology for the treatment of solid tumors. This method delivers a high dose of radiation directly to the tumor, minimizing damage to healthy tissue. Currently in the commercialization stage, its future profitability depends on the adoption of this technology in oncology practice.
Overall market profit
Alpha Tau Medical is developing an innovative radiation therapy technology for cancer treatment. Like many medical companies in the development stage, its success depends on clinical results and regulatory approval. The overall economic situation, reflected in this chart, affects the availability of investment capital needed to bring the technology to market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Alpha Tau Medical Ltd.
Alpha Tau Medical has developed an innovative radiation therapy for solid tumors that delivers alpha radiation directly to cancer cells. This chart shows analysts' speculative expectations. Future profits depend on successful clinical trials and the acceptance of this breakthrough technology by the oncology community.
%20profit%20of%20the%20company%20Alpha%20Tau%20Medical%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alpha-Tau-Medical-Ltd.&v=1772618192710 "Graph of future (projected) profit of the company Alpha Tau Medical Ltd.")
Future (predicted) profit of companies in the market segment - Miscellaneous oncology
Alpha Tau Medical has developed a breakthrough radiation therapy technology that destroys tumors from the inside with minimal damage to healthy tissue. The profitability forecasts for the oncology sector, shown in the graph, reflect the ongoing search for new treatment methods. This chart helps you appreciate how revolutionary Alpha Tau's technology could be.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Miscellaneous-oncology&v=1772618192713 "Graph of future (predicted) profits of companies in a market segment - Miscellaneous oncology")
Future (predicted) profit of the market as a whole
Alpha Tau Medical is developing an innovative radiation therapy technology for the treatment of solid tumors. Like any development-stage company, it depends on funding and clinical trial results. The favorable economic environment predicted by this schedule facilitates investment in breakthrough medical technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772618192731 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Alpha Tau Medical Ltd.
Alpha Tau Medical has developed a breakthrough radiation therapy technology that destroys tumors from the inside. The company's revenue may be limited at this stage. This chart shows how highly investors value its potential. This is a bet that its technology will become a new standard in the treatment of solid tumors.
P/S market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology, Alpha DaRT, for the treatment of solid tumors, which destroys cancer cells with minimal damage to healthy tissue. This figure reflects the average revenue estimate for the sector and helps assess the market premium for this potentially revolutionary cancer treatment method.
P/S of the market as a whole
Alpha Tau Medical has developed an innovative radiation therapy technology, Alpha DaRT, for the treatment of solid tumors. This method delivers a high dose of radiation directly to the tumor, minimizing damage to healthy tissue. This chart correlates market valuations of companies with actual revenues, which is important for contextualizing the evaluation of advanced medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Alpha Tau Medical Ltd.
Alpha Tau Medical has developed innovative radiation therapy for the treatment of solid tumors. This chart reflects investors' high valuation of its potential future revenue. This valuation is a bet that its Alpha DaRT technology will become a new standard of cancer treatment, particularly for inoperable tumors.
%20P%2FS%20Alpha%20Tau%20Medical%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alpha-Tau-Medical-Ltd.&v=1772618192789 "The graph of the company's future (projected) P/S Alpha Tau Medical Ltd.")
Future (projected) P/S of the market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology for the treatment of solid tumors. This chart compares market expectations for its future revenue with other oncology companies. The valuation reflects investors' belief in the potential of this new method to destroy cancer cells with minimal damage to healthy tissue.
%20P%2FS%20market%20segment%20graph%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Miscellaneous-oncology&v=1772618192795 "Future (projected) P/S market segment graph - Miscellaneous oncology")
Future (projected) P/S of the market as a whole
Alpha Tau Medical is developing an innovative radiation therapy technology for the treatment of solid tumors. The company is in clinical trials. Its valuation depends entirely on the success of this technology. This graph of general market expectations is irrelevant for Alpha Tau, as its potential lies in its revolutionary approach to cancer treatment, not in economics.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772618192797 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Alpha Tau Medical Ltd.
This figure reflects revenue for Alpha Tau Medical, a company developing an innovative radiation therapy method for treating solid tumors. While the company is in the clinical trials and approval stages, it does not yet generate stable revenue from commercial sales. Any revenue likely comes from grants or early sales during research.
Sales of companies in the market segment - Miscellaneous oncology
Alpha Tau Medical has developed a breakthrough cancer radiation therapy technology called Alpha DaRT, which enables the precise destruction of solid tumors while minimizing damage to healthy tissue. This chart shows revenue in the oncology equipment sector. It reflects the ongoing search for more effective and safe cancer treatments, where Alpha Tau's innovative approach could fill an important niche.
Overall market sales
Alpha Tau Medical has developed an innovative radiation therapy technology for the treatment of solid tumors. The company's success depends on the results of clinical trials and the implementation of its method in clinical practice. The economic cycles reflected in this graph do not directly affect demand for cancer treatment, but overall economic growth provides funding for medical innovation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Alpha Tau Medical Ltd.
Alpha Tau Medical is developing an innovative cancer radiation therapy technology that utilizes alpha radiation directly within tumors. This revenue projection is speculative. Its dynamics reflect analysts' confidence in the clinical success and potential adoption of this breakthrough technology in oncology practices worldwide.
%20sales%20of%20the%20company%20Alpha%20Tau%20Medical%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alpha-Tau-Medical-Ltd.&v=1772618192900 "Schedule of future (projected) sales of the company Alpha Tau Medical Ltd.")
Future (projected) sales of companies in the market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology, Alpha DaRT, for the treatment of solid tumors. This method delivers alpha-emitting particles directly to the tumor, destroying cancer cells. This graph shows forecasts for the oncology sector, reflecting expectations for new, more effective, and gentle radiation therapy methods.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Miscellaneous-oncology&v=1772618192923 "Schedule of future (projected) sales of companies in the market segment - Miscellaneous oncology")
Future (projected) sales of the market as a whole
Alpha Tau Medical has developed an innovative radiation therapy technology for the treatment of solid tumors. The company's success depends on the results of clinical trials and the acceptance of the technology by the medical community. A stable economic environment is essential for ensuring funding for healthcare systems capable of implementing such advanced treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772618192974 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Alpha Tau Medical Ltd.
Alpha Tau Medical has developed a breakthrough radiation therapy technology for the treatment of solid tumors. The company is in the early stages of commercialization. This chart shows its transition from pure R&D to revenue generation. Its ability to achieve profitability will depend on the speed of adoption of its technology in clinics worldwide.
Market segment marginality - Miscellaneous oncology
Alpha Tau Medical has developed an innovative alpha-radiotherapy technology for the treatment of solid tumors. This chart compares the company's profitability with other companies in the oncology sector. For a company whose product is in clinical trials and commercialization, staying ahead of the competition will depend on the successful implementation of its unique technology.
Market marginality as a whole
Alpha Tau Medical develops innovative radiation therapy technology for the treatment of solid tumors. Like other biotech companies, its success is not dependent on the general economic cycles reflected in this chart. The company's value is determined solely by the results of clinical trials and the potential of its technology to revolutionize cancer treatment.
Employees in the company, segment and market as a whole
Number of employees in the company Alpha Tau Medical Ltd.
Alpha Tau Medical has developed an innovative radiation therapy for the treatment of solid tumors. This graph shows the team working on the commercialization of this breakthrough technology. The growth of the team is directly related to clinical trials conducted worldwide and preparations for market launch.
Share of the company's employees Alpha Tau Medical Ltd. within the market segment - Miscellaneous oncology
Alpha Tau Medical is developing an innovative radiation therapy technology for the treatment of solid tumors. Currently in clinical trials, its team consists of physicists, engineers, and clinicians. This schedule reflects its focus on research and development: a small staff represents the spearhead of the attack on cancer using this new technology.
Number of employees in the market segment - Miscellaneous oncology
Alpha Tau Medical has developed an innovative radiation therapy technology for treating solid tumors that delivers alpha radiation directly to cancer cells. This graph shows the commercialization path of this breakthrough medical technology. The growing number of physicists, engineers, and clinicians reflects the expansion of clinical trials and preparation for market entry.
Number of employees in the market as a whole
Alpha Tau Medical develops innovative radiation therapy for the treatment of solid tumors. Its team consists of physicists, engineers, and medical professionals. This employment graph demonstrates that companies at the intersection of medicine and nuclear physics are creating unique jobs, the growth of which depends on the success of clinical trials and the implementation of new technologies, rather than on the overall economic climate.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical has developed a breakthrough radiation therapy technology, Alpha-DaRT, which destroys solid tumors with minimal damage to surrounding tissue. This graph reflects the enormous cost per employee, demonstrating that investors are not evaluating production capacity, but the unique technology and its potential for cancer treatment.
%20of%20the%20company%20Alpha%20Tau%20Medical%20Ltd.%20(DRTS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alpha-Tau-Medical-Ltd.-DRTS&v=1772618193351 "Chart of market capitalization per employee (in thousands of dollars) of the company Alpha Tau Medical Ltd. (DRTS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Miscellaneous oncology
Alpha Tau Medical is developing an innovative radiation therapy technology for cancer treatment. In the field of medical innovation, this chart reflects the market's belief in breakthrough potential. The high market capitalization per employee indicates that investors highly value the uniqueness of their technology and its potential to change the standard of cancer treatment.
%20by%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Miscellaneous-oncology&v=1772618193373 "Market capitalization per employee (in thousands of dollars) by market segment - Miscellaneous oncology")
Market capitalization per employee (in thousands of dollars) for the overall market
Alpha Tau Medical has developed an innovative radiation therapy technology for the treatment of solid tumors. This valuation reflects the company's position at the forefront of oncology. Its market capitalization is based on the potential of this unique technology. Even a small team of physicists and doctors can create a treatment method that will command a significant market value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772618193388 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical is developing a new radiation therapy technology (Alpha DaRT) for cancer treatment. They are a company at the intersection of medicine and physics, currently in clinical trials. They are not profitable. This graph shows their loss per employee—the cost of R&D and clinical trials for their innovative method.
%20Chart%20Alpha%20Tau%20Medical%20Ltd.%20(DRTS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alpha-Tau-Medical-Ltd.-DRTS&v=1772618193412 "Company Profit Per Employee (in thousands of dollars) Chart Alpha Tau Medical Ltd. (DRTS)")
Profit per employee (in thousands of dollars) in the market segment - Miscellaneous oncology
Alpha Tau Medical is an Israeli company that has developed a new radiation therapy technology (Alpha DaRT) for the treatment of solid tumors. The technology is currently in the commercialization stage. This figure reflects a combination of ongoing R&D expenditures and the initial, high costs of establishing a dedicated sales team and clinical support.
%20in%20the%20market%20segment%20-%20Miscellaneous%20oncology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Miscellaneous-oncology&v=1772618193451 "Chart of profit per employee (in thousands of dollars) in the market segment - Miscellaneous oncology")
Profit per employee (in thousands of dollars) for the market as a whole
Alpha Tau Medical is developing an innovative cancer radiation therapy technology (Alpha DaRT). It is a medtech company in the clinical trials stage. The profit per employee here is not based on current sales. The graph shows the investment "burned" per employee (physicist, engineer, physician) to bring this complex technology to market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772618193491 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical is developing innovative radiation therapy for the treatment of solid tumors. This graph shows the company's progress toward commercialization. Revenue per employee growth will reflect the success of clinical trials and the launch of sales of their unique Alpha DaRT technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alpha-Tau-Medical-Ltd.-DRTS&v=1772618193546 "Sales chart per company employee Alpha Tau Medical Ltd. (DRTS)")
Sales per employee in the market segment - Miscellaneous oncology
Alpha Tau Medical (DRTS) is an oncology company that has developed a new technology, Alpha DaRT, for treating solid tumors by delivering alpha radiation directly to the tumor. This graph shows the revenue (from implementation and partnerships) generated by each employee. It is an indicator of progress in commercializing their unique medical technology.
Sales per employee for the market as a whole
Alpha Tau Medical is developing an innovative radiation therapy (Alpha DaRT) for the treatment of solid tumors. They are a MedTech company in the clinical trials and commercialization phase. This metric reflects their success in selling or leasing their equipment to clinics. Growth will signal recognition of their technology.
Short shares by company, segment and market as a whole
Shares shorted by company Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical is developing an innovative cancer radiation therapy (Alpha DaRT). This chart shows bearish bets. Bears are betting on the high risk that this promising but unproven technology will fail to demonstrate its safety and efficacy in large trials or fail to receive regulatory approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alpha-Tau-Medical-Ltd.-DRTS&v=1772618193625 "Short Shares Chart for the Company Alpha Tau Medical Ltd. (DRTS)")
Shares shorted by market segment - Miscellaneous oncology
Alpha Tau Medical is developing an innovative radiation therapy (Alpha DaRT) for treating cancer tumors. This chart shows bearish sentiment. The "shorts" here are betting that their new technology will fail to prove effective in clinical trials or will prove too complex for widespread use.
Shares shorted by the overall market
Alpha Tau Medical is developing innovative radiation therapy for cancer treatment. The technology promises high efficacy with minimal side effects. This chart measures overall market fear. When investors panic, they often ignore scientific potential and sell biotech stocks without stable profits, making the sector highly volatile.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical is developing a new radiation therapy technology for cancer. The stock is highly speculative. This chart can surge above 70 on positive clinical data or regulatory news. Below 30 is often associated with setbacks, delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alpha-Tau-Medical-Ltd.-DRTS&v=1772618193725 "RSI 14 indicator chart for the company's stock Alpha Tau Medical Ltd. (DRTS)")
RSI 14 Market Segment - Miscellaneous oncology
Alpha Tau (DRTS) is "radiation" against cancer. Their technology (Alpha DaRT) *embeds* "alpha-emitting" seeds *directly into the tumor*. RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. The chart helps us understand: is DRTS's volatility a reflection of their technology, or is the entire biotech sector overheated?
RSI 14 for the overall market
Alpha Tau (DRTS) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DRTS (Alpha Tau Medical Ltd.)
Alpha Tau (DRTS) is an Israeli company that developed Alpha DaRT, a technology for treating solid tumors by injecting alpha-particle-emitting "seeds." This chart shows the average target price. It reflects analysts' speculative valuations of this innovative oncology technology and its clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DRTS-Alpha-Tau-Medical-Ltd.&v=1772618193873 "A chart showing analyst consensus forecasts for the expected stock price. DRTS (Alpha Tau Medical Ltd.)")
The difference between the consensus estimate and the actual stock price DRTS (Alpha Tau Medical Ltd.)
Alpha Tau Medical is an Israeli company developing a new form of radiation therapy (Alpha DaRT). Their technology involves injecting radioactive seeds directly into solid tumors to destroy them from the inside. This chart reflects analysts' speculative expectations for this breakthrough, yet unproven, R&D platform and its clinical data.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DRTS-Alpha-Tau-Medical-Ltd.&v=1772618193890 "A chart showing the difference between the consensus forecast and the actual stock price. DRTS (Alpha Tau Medical Ltd.)")
Analyst consensus forecast for stock prices by market segment - Miscellaneous oncology
Alpha Tau Medical is an oncology company that developed Alpha DaRT, a technology that implants radioactive "seeds" into tumors, destroying them from the inside. This chart shows general expectations for the oncology sector, reflecting experts' confidence in this new form of localized radiation therapy.
Analysts' consensus forecast for the overall market share price
Alpha Tau Medical (DRTS) is an oncology company that developed a new technology, Alpha DaRT. It delivers alpha radiation directly into solid tumors, destroying them. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough, but not yet fully adopted, medical technologies.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Alpha Tau Medical Ltd.
Alpha Tau is an Israeli oncology company with a unique technology called Alpha DaRT. This is radiation delivered directly into the tumor (via seeds), killing cancer without affecting healthy tissue. This graph is a barometer of their R&D. It likely reflects their clinical data, their progress toward FDA approval, and the market's confidence in their breakthrough, localized cancer treatment.
AKIMA Market Segment Index - Miscellaneous oncology
Alpha Tau (DRTS) is an Israeli medtech innovator in oncology; the company has developed a unique technology (Alpha DaRT) that delivers alpha radiation directly into solid tumors. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this breakthrough (R&D) technology (DRTS) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Alpha Tau is an Israeli medtech company that developed Alpha DaRT technology for treating solid tumors with alpha radiation. This chart, which reflects the market average, provides context. It helps assess how this innovative oncology technology, currently in clinical development, compares to overall macroeconomic trends.
